Product logins

Find logins to all Clarivate products below.


Biomarker-Driven Prescribing in Oncology | Pharmacor | G7 | 2014

Owing to the heterogeneity of cancer, oncology markets are increasingly focusing on personalized therapy approaches that are expected to provide greater efficacy gains. Driving this trend are biomarkers that effectively identify the niche patient populations most likely to respond and derive benefit from targeted therapies. Biomarkers are already entrenched in oncology indications such as breast, colorectal, gastric, and non-small-cell lung cancers and malignant melanoma, where biomarker-driven prescribing has proven highly lucrative.

Related Market Assessment Reports

Report
Biosimilars – Forecast – Oncology
In 2024, sales of branded MAb biologics in oncology exceeded $48 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled $5.9 billion…
Report
Oncology Brand Tracker – Immune Checkpoint Inhibitors | 2020
Driven by DRG’s oncology expertise and real-world data capabilities, the Real World Brand Tracker is an interactive dashboard of regularly updated U.S. claims data that monitors and highlights…
Report
Biosimilars – Current Treatment – Oncology
In 2019, Amgen / Allergan’s trastuzumab biosimilar Kanjinti and bevacizumab biosimilar Mvasi were the first monoclonal antibody (MAb) biosimilars launched in the United States, followed by…
Report
Chimeric Antigen Receptor (CAR) T-Cell Therapy – Access & Reimbursement – Access & Reimbursement – Chimeric Antigen Receptor (CAR) T-Cell Therapy (US)
Ever since Novartis’s Kymriah became the first chimeric antigen receptor (CAR) T-cell therapy approved by the FDA for a cancer indication (acute lymphoblastic leukemia) in 2017, this class of…
Report
Biosimilars | Market Events and Forecast | Oncology | 2025
In 2023, sales of branded MAb biologics in oncology exceeded $47 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled approximately $5.54…